CRBU news

Latest 1 stories · newest Jun 11, 2026

CRBU

Caribou's vispa-cel shows 82% response rate in second-line lymphoma trial

Caribou Biosciences reported long-term data for vispa-cel CAR-T therapy showing 82% overall response rate and 67% complete response rate in second-line large B cell lymphoma patients, with a well-tolerated safety profile. The results support the company's planned ANTLER-3 phase 3 pivotal trial and p…

Other Jun 11, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same CRBU feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/CRBU/newsSTART FREE